durapatite has been researched along with sirolimus in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abizaid, A; Bonan, R; Costa, JR; Costa, R; Feres, F; Mattos, LA; Siqueira, D; Sousa, AG; Sousa, JE; Staico, R; Tanajura, LF | 1 |
| Peters-Krabbendam, I; Serruys, PW; Sorop, O; van Beusekom, HM; van der Giessen, WJ | 1 |
| Abizaid, A; Bonan, R; Costa, JR; Costa, R; Feres, F; Maldonado, G; Siqueira, D; Sousa, AG; Sousa, JE; Staico, R; Tanajura, LF | 1 |
| Alviar, CL; Budzynski, W; Granada, JF; Kaluza, GL; Kleiman, NS; Lev, EI; Potts, P; Raizner, AE; Smith, D; Tellez, A; Tsui, M; Wang, M | 1 |
| Dong, JY; Guo, QQ; Liu, C; Liu, H; Liu, SH; Tan, WY; Wan, Y; Yue, LL; Zhang, D | 1 |
1 trial(s) available for durapatite and sirolimus
| Article | Year |
|---|---|
Low-dose sirolimus-eluting hydroxyapatite coating on stents does not increase platelet activation and adhesion ex vivo.
Topics: Adult; Coated Materials, Biocompatible; Drug-Eluting Stents; Durapatite; Female; Humans; Immunosuppressive Agents; Male; Materials Testing; Platelet Activation; Sirolimus; Time Factors | 2012 |
4 other study(ies) available for durapatite and sirolimus
| Article | Year |
|---|---|
Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stents; Durapatite; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Prosthesis Design; Registries; Sirolimus; Stainless Steel; Ticlopidine; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2008 |
Lowering the dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, reduces signs of delayed healing.
Topics: Angioplasty, Balloon, Coronary; Animals; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Biocompatible; Coronary Angiography; Coronary Restenosis; Coronary Vessels; Drug-Eluting Stents; Durapatite; Hyperplasia; Lipids; Materials Testing; Models, Animal; Platelet Aggregation Inhibitors; Prosthesis Design; Sirolimus; Stainless Steel; Surface Properties; Sus scrofa; Ticlopidine; Wound Healing | 2009 |
1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Durapatite; Female; Humans; Intensive Care Units; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymers; Prospective Studies; Sirolimus; Ticlopidine; Time Factors; Ultrasonography | 2009 |
Rapamycin/sodium hyaluronate binding on nano-hydroxyapatite coated titanium surface improves MC3T3-E1 osteogenesis.
Topics: Animals; Cell Differentiation; Cell Proliferation; Cells, Cultured; Coated Materials, Biocompatible; Durapatite; Hyaluronic Acid; Mice; Nanostructures; Osseointegration; Osteoblasts; Osteogenesis; Prostheses and Implants; Sirolimus; Surface Properties; Tissue Scaffolds; Titanium | 2017 |